

Increases in hepatitis C virus infection related to injection drug use among persons aged 18-30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2000-2010

Morbidity and Mortality Weekly Report

64, 453-8

Citation Report

#	ARTICLE	IF	CITATIONS
1	Toward a more accurate estimate of the prevalence of hepatitis C in the United States. <i>Hepatology</i> , 2015, 62, 1353-1363.	3.6	364
2	Reply to direct-acting antiviral drugs and hepatitis C virus: A therapeutic revolution?. <i>Cancer</i> , 2015, 121, 4269-4270.	2.0	0
3	Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1447-1462.	1.4	1
4	The role of social networks and geography on risky injection behaviors of young persons who inject drugs. <i>Drug and Alcohol Dependence</i> , 2015, 154, 229-235.	1.6	38
5	Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3552-3557.	1.1	13
6	Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014. <i>Public Health Reports</i> , 2016, 131, 65-73.	1.3	29
7	Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection. <i>PLoS ONE</i> , 2016, 11, e0165533.	1.1	14
8	Eighteen-to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. <i>Journal of Viral Hepatitis</i> , 2016, 23, 274-281.	1.0	8
9	Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. <i>Epidemiology and Infection</i> , 2016, 144, 3376-3386.	1.0	5
10	County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 323-331.	0.9	333
11	Treatment utilization among persons with opioid use disorder in the United States. <i>Drug and Alcohol Dependence</i> , 2016, 169, 117-127.	1.6	278
12	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	3.7	80
13	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. <i>Postgraduate Medical Journal</i> , 2016, 92, 356-363.	0.9	22
14	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. <i>Value in Health</i> , 2016, 19, 326-334.	0.1	30
15	Low HIV testing among persons who inject drugs—National HIV Behavioral Surveillance, 2012. <i>Drug and Alcohol Dependence</i> , 2016, 165, 270-274.	1.6	18
16	Performance of Risk-Based and Birth-Cohort Strategies for Identifying Hepatitis C Virus Infection Among People Entering Prison, Wisconsin, 2014. <i>Public Health Reports</i> , 2016, 131, 544-551.	1.3	14
17	Hepatitis C Treatment and Barriers to Eradication. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e193.	1.3	57
18	Opiate Injection-associated Infective Endocarditis in the Southeastern United States. <i>American Journal of the Medical Sciences</i> , 2016, 352, 603-608.	0.4	74

#	ARTICLE	IF	CITATIONS
19	Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?. Substance Use and Misuse, 2016, 51, 1674-1679.	0.7	13
20	Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infectious Diseases, The, 2016, 16, e196-e201.	4.6	37
21	Social context and perspectives of non-€medical prescription opioid use among young adults in Rhode Island: A qualitative study. American Journal on Addictions, 2016, 25, 659-665.	1.3	21
22	The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials, 2016, 17, 592.	0.7	36
23	Sharing of Snorting Straws and Hepatitis C Virus Infection in Pregnant Women. Obstetrics and Gynecology, 2016, 128, 234-237.	1.2	24
24	Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. Journal of Infectious Diseases, 2016, 214, 344-352.	1.9	12
25	High-impact hepatitis C virus testing for injection drug users in an urban ED. American Journal of Emergency Medicine, 2016, 34, 1108-1111.	0.7	10
26	Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus-€Infected Women. Clinical Infectious Diseases, 2016, 62, 980-985.	2.9	94
27	Detoxification from opiate drugs during pregnancy. American Journal of Obstetrics and Gynecology, 2016, 215, 374.e1-374.e6.	0.7	69
28	Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities. International Journal of Drug Policy, 2016, 31, 25-31.	1.6	50
29	The American College of Preventive Medicine Position Statement on Hepatitis C Virus Infection. American Journal of Preventive Medicine, 2016, 50, 419-426.	1.6	5
30	A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology, 2016, 90, 3773-3782.	1.5	24
31	Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama. Clinical Infectious Diseases, 2016, 62, 613-616.	2.9	6
32	Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department. Clinical Infectious Diseases, 2016, 62, 1059-1065.	2.9	66
33	Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. Clinical Infectious Diseases, 2016, 62, 1066-1071.	2.9	43
34	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. Journal of Virology, 2016, 90, 152-166.	1.5	17
35	Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine, 2017, 129, 102-110.	0.9	22
36	Using database linkages to monitor the continuum of care for hepatitis C virus among syringe exchange clients: Experience from a pilot intervention. International Journal of Drug Policy, 2017, 42, 22-25.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Retention in buprenorphine treatment is associated with improved HCV care outcomes. <i>Journal of Substance Abuse Treatment</i> , 2017, 75, 38-42.	1.5	32
38	Hepatitis C Antibody Testing in a Commercially Insured Population, 2005–2014. <i>American Journal of Preventive Medicine</i> , 2017, 52, 625-631.	1.6	26
39	Geographic Disparities in Access to Syringe Services Programs Among Young Persons With Hepatitis C Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2017, 65, 514-517.	2.9	58
40	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral Era. <i>Current Epidemiology Reports</i> , 2017, 4, 174-185.	1.1	48
41	A Public Health Approach to Hepatitis C in an Urban Setting. <i>American Journal of Public Health</i> , 2017, 107, 922-926.	1.5	14
42	Hepatitis C virus infection in children and adolescents. <i>Hepatology Communications</i> , 2017, 1, 87-98.	2.0	64
43	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, S1-S23.	0.5	29
44	Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. <i>Drug and Alcohol Dependence</i> , 2017, 176, 89-95.	1.6	58
45	Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2017, 66, 1102-1110.	3.6	88
46	Down in the valley: Trajectories of injection initiation among young injectors in California’s Central Valley. <i>International Journal of Drug Policy</i> , 2017, 44, 41-49.	1.6	24
47	Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1373-1380.	1.1	68
48	The safety and effectiveness of ledipasvir/sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. <i>Hepatology</i> , 2017, 66, 371-378.	3.6	152
49	Self-reported participation in voluntary nonprescription syringe sales in California’s Central Valley. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 677-685.	0.7	21
50	Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3193-3199.	1.1	0
51	Partner Relationships and Injection Sharing Practices among Rural Appalachian Women. <i>Women's Health Issues</i> , 2017, 27, 652-659.	0.9	18
52	The oncologic burden of hepatitis C virus infection: A clinical perspective. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 411-431.	157.7	88
53	Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs. <i>Journal of Primary Prevention</i> , 2017, 38, 481-494.	0.8	6
54	Fentanyl in the US heroin supply: A rapidly changing risk environment. <i>International Journal of Drug Policy</i> , 2017, 46, 107-111.	1.6	337

#	ARTICLE	IF	CITATIONS
55	Receipt and timing of HIV drug resistance testing in six U.S. jurisdictions. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1567-1575.	0.6	9
56	Impact of Food Insecurity on Depressive Symptoms Among HIV/HCV Co-infected People. <i>AIDS and Behavior</i> , 2017, 21, 3464-3472.	1.4	6
57	Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014. <i>JAMA Pediatrics</i> , 2017, 171, 747.	3.3	214
58	Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 86-94.	1.6	23
59	The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto Rico. <i>BMC Health Services Research</i> , 2017, 17, 232.	0.9	3
60	Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. <i>Harm Reduction Journal</i> , 2017, 14, 25.	1.3	35
61	State HCV Incidence and Policies Related to HCV Preventive and Treatment Services For Persons Who Inject Drugs – United States, 2015–2016. <i>American Journal of Transplantation</i> , 2017, 17, 1945-1948.	2.6	6
62	Opt-out HIV and Hepatitis C Testing at the Dallas County Jail: Uptake, Prevalence, and Demographic Characteristics of Testers. <i>Public Health Reports</i> , 2017, 132, 617-621.	1.3	33
63	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1035-1042.	2.9	42
64	Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers. <i>PLoS ONE</i> , 2017, 12, e0188624.	1.1	3
65	Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. <i>PLoS Pathogens</i> , 2017, 13, e1006235.	2.1	47
66	Neonatal Abstinence Syndrome in East Tennessee: Characteristics and Risk Factors among Mothers and Infants in One Area of Appalachia. <i>Journal of Health Care for the Poor and Underserved</i> , 2017, 28, 1393-1408.	0.4	19
67	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. <i>JCI Insight</i> , 2017, 2, .	2.3	129
68	The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions. <i>Current HIV/AIDS Reports</i> , 2018, 15, 96-112.	1.1	123
69	Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned. <i>Current HIV/AIDS Reports</i> , 2018, 15, 113-119.	1.1	14
70	Tennessee’s In-state Vulnerability Assessment for a “Rapid Dissemination of Human Immunodeficiency Virus or Hepatitis C Virus Infection” Event Utilizing Data About the Opioid Epidemic. <i>Clinical Infectious Diseases</i> , 2018, 66, 1722-1732.	2.9	22
71	Update on the management of hepatitis B and C infections in the neonatal period. <i>Seminars in Perinatology</i> , 2018, 42, 185-190.	1.1	6
72	Hepatitis C Virus Knowledge Among Pregnant Women with Opioid Use Disorder. <i>Maternal and Child Health Journal</i> , 2018, 22, 1208-1216.	0.7	7

#	ARTICLE	IF	CITATIONS
73	Differences in time to injection onset by drug in California: Implications for the emerging heroin epidemic. <i>Drug and Alcohol Dependence</i> , 2018, 185, 253-259.	1.6	16
74	Shining a LIGHT Into Drug Darkness. <i>Journal for Nurse Practitioners</i> , 2018, 14, 463-469.e3.	0.4	1
75	Harnessing the language of overdose prevention to advance evidence-based responses to the opioid crisis. <i>International Journal of Drug Policy</i> , 2018, 55, 77-79.	1.6	27
76	The opioid epidemic and injection drug use: MIPIE and health harms related to the injection of prescription opioids. <i>International Journal of Drug Policy</i> , 2018, 57, 130-132.	1.6	7
77	Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. <i>Epidemiology and Infection</i> , 2018, 146, 508-514.	1.0	4
78	Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. <i>Journal of General Internal Medicine</i> , 2018, 33, 551-557.	1.3	36
79	Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. <i>American Journal of Public Health</i> , 2018, 108, 175-181.	1.5	534
80	Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. <i>Infection, Genetics and Evolution</i> , 2018, 58, 77-82.	1.0	12
81	Drug Use and Incarceration among Rural Appalachian Women: Findings From a Jail Sample. <i>Substance Use and Misuse</i> , 2018, 53, 931-941.	0.7	33
82	Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. <i>Journal of Infectious Diseases</i> , 2018, 217, 1020-1023.	1.9	6
83	Hepatitis C Virus Screening Among Children Exposed During Pregnancy. <i>Pediatrics</i> , 2018, 141, .	1.0	85
84	Common mental disorders and psychological adjustment among individuals seeking HIV testing: a study protocol to explore implications for mental health care systems. <i>International Journal of Mental Health Systems</i> , 2018, 12, 16.	1.1	8
85	Addressing the growing opioid and heroin abuse epidemic: a call for medical school curricula. <i>Medical Education Online</i> , 2018, 23, 1466574.	1.1	29
86	Feasibility of ecological momentary assessment to study mood and risk behavior among young people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2018, 187, 227-235.	1.6	32
87	Scaling up HCV prevention and treatment interventions in rural United States model projections for tackling an increasing epidemic. <i>Addiction</i> , 2018, 113, 173-182.	1.7	71
88	Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. <i>Journal of Viral Hepatitis</i> , 2018, 25, 28-36.	1.0	4
89	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. <i>Hepatology</i> , 2018, 67, 837-846.	3.6	61
90	The rise of the opioid epidemic and hepatitis C positive organs: A new era in liver transplantation. <i>Hepatology</i> , 2018, 67, 1600-1608.	3.6	62

#	ARTICLE	IF	CITATIONS
91	High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. <i>Journal of Urban Health</i> , 2018, 95, 71-82.	1.8	22
92	Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 310-316.	1.1	12
93	Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse. <i>Journal of Pediatrics</i> , 2018, 192, 159-164.	0.9	38
94	How to eliminate HCV in people who inject drugs in the USA. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 134-135.	4.6	8
95	Needlestick Injuries Among Emergency Medical Services Providers in Urban and Rural Areas. <i>Journal of Community Health</i> , 2018, 43, 518-523.	1.9	13
96	Prevalence of Hepatitis C Screening, Testing, and Care Experience Among Young Adults Who Use Prescription Opioids Nonmedically. <i>Journal of Adolescent Health</i> , 2018, 62, 114-117.	1.2	2
97	Correlates of Injection Drug Use Among Rural Appalachian Women. <i>Journal of Rural Health</i> , 2018, 34, 31-41.	1.6	28
98	Prevalence of Maternal Hepatitis C Virus Infection in Ohio. <i>Obstetrics and Gynecology</i> , 2018, 132, 708-716.	1.2	15
99	Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia. <i>Journal of Addictive Diseases</i> , 2018, 37, 1-4.	0.8	9
100	HIV and the Liver. , 2018, , 536-555.e7.		1
101	Hepatitis C Within a Single Health System: Progression Along the Cascade to Cure Is Higher for Those With Substance Misuse When Linked to a Clinic With Embedded Support Services. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy202.	0.4	9
102	A large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana, 2015. <i>EBioMedicine</i> , 2018, 37, 374-381.	2.7	51
103	Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine. <i>Frontiers in Immunology</i> , 2018, 9, 2577.	2.2	1
104	Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings. <i>Western Journal of Emergency Medicine</i> , 2018, 19, 1057-1064.	0.6	13
105	Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 532.	1.3	95
106	Qualitative case study of needle exchange programs in the Central Appalachian region of the United States. <i>PLoS ONE</i> , 2018, 13, e0205466.	1.1	21
107	Prevalence of hepatitis C viral infection among injecting drug users in a Saudi Arabian hospital: A point cross sectional survey. <i>Journal of Public Health in Africa</i> , 2018, 9, 726.	0.2	5
108	HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. <i>PLoS ONE</i> , 2018, 13, e0204795.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Peer-to-peer injection: Demographic, drug use, and injection-related risk factors. <i>International Journal of Drug Policy</i> , 2018, 61, 44-51.	1.6	8
110	Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. <i>AIDS Patient Care and STDs</i> , 2018, 32, 529-537.	1.1	86
111	HIV Prevention in Rural Appalachian Jails: Implications for Re-entry Risk Reduction Among Women Who Use Drugs. <i>AIDS and Behavior</i> , 2018, 22, 4009-4018.	1.4	12
112	Hepatitis C Virus in Women of Childbearing Age, Pregnant Women, and Children. <i>American Journal of Preventive Medicine</i> , 2018, 55, 633-641.	1.6	39
113	Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. <i>Clinical Infectious Diseases</i> , 2018, 67, 1493-1497.	2.9	45
114	Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. <i>JAMA Pediatrics</i> , 2018, 172, 1029.	3.3	141
115	Trends in non-medical prescription opioids and heroin co-use among adults, 2003â€“2014. <i>Addictive Behaviors</i> , 2018, 86, 17-23.	1.7	21
116	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 371-393.	1.9	27
117	The Road to Hepatitis C Virus Cure. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 481-493.	1.9	3
118	Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: A systematic review. <i>Drug and Alcohol Dependence</i> , 2018, 188, 239-250.	1.6	50
119	Federal Response to the Opioid Crisis. <i>Current HIV/AIDS Reports</i> , 2018, 15, 293-301.	1.1	39
120	Diffusion of medication drop-boxes in North Carolina from 2007 to 2016. <i>Addictive Behaviors</i> , 2018, 86, 44-50.	1.7	10
121	Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. <i>Paediatric and Perinatal Epidemiology</i> , 2018, 32, 401-410.	0.8	12
122	Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013â€“2016. <i>Advances in Therapy</i> , 2018, 35, 1087-1102.	1.3	22
123	HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia. <i>Current HIV/AIDS Reports</i> , 2018, 15, 308-314.	1.1	5
124	Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention. <i>Current HIV/AIDS Reports</i> , 2018, 15, 324-335.	1.1	21
125	Direct-acting antiviral treatment of acute hepatitis C virus infections. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 599-610.	2.0	3
126	Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001â€“2012. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy144.	0.4	10

#	ARTICLE	IF	CITATIONS
127	Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition. <i>Current HIV/AIDS Reports</i> , 2018, 15, 276-282.	1.1	21
128	Pharmacistsâ€™ role in harm reduction: a survey assessment of Kentucky community pharmacistsâ€™ willingness to participate in syringe/needle exchange. <i>Harm Reduction Journal</i> , 2018, 15, 4.	1.3	23
129	Unique Challenges of Hepatitis C in Infants, Children, and Adolescents. <i>Clinical Therapeutics</i> , 2018, 40, 1299-1307.	1.1	22
130	Hepatitis C virus infection in children: How do we prevent it and how do we treat it?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 689-694.	2.0	26
131	Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. <i>Current HIV/AIDS Reports</i> , 2018, 15, 315-323.	1.1	25
132	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
133	Knowledge of Hepatitis C Risk Factors is Lower in High Incidence Regions. <i>Journal of Community Health</i> , 2019, 44, 12-15.	1.9	6
134	Trends in Adolescent Heroin and Injection Drug Use in Nine Urban Centers in the U.S., 1999â€“2017. <i>Journal of Adolescent Health</i> , 2019, 65, 210-215.	1.2	14
135	Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017. <i>Infectious Diseases: Research and Treatment</i> , 2019, 12, 117863371984138.	0.7	14
136	Costâ€ effectiveness of scalingâ€ HCV prevention and treatment in the United States for people who inject drugs. <i>Addiction</i> , 2019, 114, 2267-2278.	1.7	28
137	Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Usersâ€ Findings from a Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2345.	1.2	10
138	How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis. <i>Journal of Adolescent Health</i> , 2019, 65, 177-180.	1.2	22
139	The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance. <i>Preventive Medicine</i> , 2019, 128, 105740.	1.6	19
140	Explaining Pharmacy Studentsâ€™ Dispensing Intentions in Substance Abuse-Related Gray Areas Using the Theory of Planned Behavior. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 6767.	0.7	2
141	Hepatitis C virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 477-487.	3.7	117
142	I could take the judgment if you could just provide the service: non-prescription syringe purchase experience at Arizona pharmacies, 2018. <i>Harm Reduction Journal</i> , 2019, 16, 57.	1.3	22
143	Social norms associated with nonmedical opioid use in rural communities: a systematic review. <i>Translational Behavioral Medicine</i> , 2019, 9, 1224-1232.	1.2	19
144	Changes in Reported Injection Behaviors Following the Public Health Response to an HIV Outbreak Among People Who Inject Drugs: Indiana, 2016. <i>AIDS and Behavior</i> , 2019, 23, 3257-3266.	1.4	11

#	ARTICLE	IF	CITATIONS
145	Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20190334.	1.5	9
146	Geographic Trends, Patient Characteristics, and Outcomes of Infective Endocarditis Associated With Drug Abuse in the United States From 2002 to 2016. <i>Journal of the American Heart Association</i> , 2019, 8, e012969.	1.6	103
147	Opioid epidemic and liver disease. <i>JHEP Reports</i> , 2019, 1, 240-255.	2.6	18
148	Distributive Syringe Sharing and Use of Syringe Services Programs (SSPs) Among Persons Who Inject Drugs. <i>AIDS and Behavior</i> , 2019, 23, 3306-3314.	1.4	11
149	Potential disease burden of patients with substance abuse undergoing major abdominal surgery: A propensity score-matched analysis. <i>Surgery</i> , 2019, 166, 1181-1187.	1.0	4
150	Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999–2016. <i>Journal of Infectious Diseases</i> , 2020, 221, 408-418.	1.9	19
151	A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. <i>Health Affairs</i> , 2019, 38, 287-294.	2.5	60
152	Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. <i>Harm Reduction Journal</i> , 2019, 16, 33.	1.3	54
153	Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system. <i>PLoS ONE</i> , 2019, 14, e0216459.	1.1	20
154	Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. <i>Scientific Reports</i> , 2019, 9, 9251.	1.6	42
155	The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review. <i>Journal of Medical Virology</i> , 2019, 91, 1707-1724.	2.5	16
156	Acute Hepatitis C. , 2019, , 197-217.		0
157	Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users. <i>Infectious Diseases and Therapy</i> , 2019, 8, 417-428.	1.8	5
158	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. <i>American Journal of Epidemiology</i> , 2019, 188, 1539-1551.	1.6	29
159	Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-6.	0.8	10
160	Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1958.	1.2	19
161	Acute HCV Treatment: What Should We Do in the DAA Era?. <i>Current Hepatology Reports</i> , 2019, 18, 216-221.	0.4	0
162	Rural risk environments for hepatitis c among young adults in appalachian kentucky. <i>International Journal of Drug Policy</i> , 2019, 72, 47-54.	1.6	29

#	ARTICLE	IF	CITATIONS
163	Testing for Hepatitis C in Pregnancy: the Time Has Come for Routine Rather than Risk-Based. <i>Current Hepatology Reports</i> , 2019, 18, 206-215.	0.4	7
164	Estimated cost of comprehensive syringe service program in the United States. <i>PLoS ONE</i> , 2019, 14, e0216205.	1.1	14
165	Contact tracing for hepatitis C: The case for novel screening strategies as we strive for viral elimination. <i>International Journal of Drug Policy</i> , 2019, 72, 33-39.	1.6	19
166	Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz125.	0.4	7
167	Barriers to using new needles encountered by rural Appalachian people who inject drugs: implications for needle exchange. <i>Harm Reduction Journal</i> , 2019, 16, 23.	1.3	20
168	Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. <i>Epidemics</i> , 2019, 27, 86-95.	1.5	21
169	Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13514.	0.8	56
170	Rising role of prescription drugs as a portal to injection drug use and associated mortality in Baltimore, Maryland. <i>PLoS ONE</i> , 2019, 14, e0213357.	1.1	12
171	Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 311-322.	1.0	8
172	Treatment and monitoring of children with chronic hepatitis C in the Pre-DAAs era: A European survey of 38 paediatric specialists. <i>Journal of Viral Hepatitis</i> , 2019, 26, 961-968.	1.0	15
173	Opioid agonist treatment and the process of injection drug use initiation. <i>Drug and Alcohol Dependence</i> , 2019, 197, 354-360.	1.6	26
174	Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: a cautionary tale. <i>Annals of Epidemiology</i> , 2019, 34, 12-17.	0.9	31
175	Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 69, 514-522.	2.9	20
176	Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. <i>Infection, Genetics and Evolution</i> , 2019, 71, 1-6.	1.0	2
177	Acute Hepatitis C. , 2019, , 45-65.		0
178	Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	5
179	New Face of Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1782-1788.	1.1	19
180	Management of Hepatitis C. <i>Gastroenterology Nursing</i> , 2019, Publish Ahead of Print, 22-27.	0.2	0

#	ARTICLE	IF	CITATIONS
181	Drug Misuse and Hepatitis C Virus Infection Profiles for Three Generations of Patients Being Monitored for Prescription Drug Adherence. <i>Journal of Addiction Medicine</i> , 2019, 13, 123-130.	1.4	1
182	HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco. <i>PLoS ONE</i> , 2019, 14, e0226166.	1.1	12
183	Mortality, morbidity, and cardiac surgery in Injection Drug Use (IDU)-associated versus non-IDU infective endocarditis: The need to expand substance use disorder treatment and harm reduction services. <i>PLoS ONE</i> , 2019, 14, e0225460.	1.1	40
184	“We don't get much of a voice about anything” perspectives on photovoice among people who inject drugs. <i>Harm Reduction Journal</i> , 2019, 16, 61.	1.3	10
185	Opioid-Related Diagnoses and Concurrent Claims for HIV, HBV, or HCV among Medicare Beneficiaries, United States, 2015. <i>Journal of Clinical Medicine</i> , 2019, 8, 1768.	1.0	3
186	Hepatitis C Virus Antibody Testing Among 13- to 21-Year-Olds in a Large Sample of US Federally Qualified Health Centers. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2245.	3.8	10
187	Hepatitis C Virus Infection in Indigenous Populations in the United States and Canada. <i>Epidemiologic Reviews</i> , 2019, 41, 158-167.	1.3	14
188	Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. <i>Pain Practice</i> , 2019, 19, 443-454.	0.9	9
189	Systemic Issues in the Opioid Epidemic: Supporting the Individual, Family, and Community. <i>International Journal of Mental Health and Addiction</i> , 2019, 17, 1214-1228.	4.4	7
190	Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. <i>Hepatology</i> , 2019, 69, 1020-1031.	3.6	374
191	HIV conspiracy theory beliefs mediates the connection between HIV testing attitudes and HIV prevention self-efficacy. <i>Journal of American College Health</i> , 2019, 67, 661-673.	0.8	6
192	In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. <i>Antiviral Research</i> , 2019, 162, 136-141.	1.9	4
193	Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City. <i>Drug and Alcohol Dependence</i> , 2019, 194, 453-459.	1.6	10
194	Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. <i>Drug and Alcohol Dependence</i> , 2019, 195, 114-120.	1.6	31
195	Increased HCV Screening Yields Discordant Gains in Diagnoses Among Urban and Rural Veteran Populations in Texas: Results of a Statewide Quality Improvement Initiative. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 112-122.	0.4	2
196	Clinical Epidemiology of Hepatitis C Virus. , 2019, , 149-170.		1
197	National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 806-821.	0.9	2
198	(Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States. <i>Hepatology</i> , 2019, 69, 1832-1834.	3.6	0

#	ARTICLE	IF	CITATIONS
199	Promising roles for pharmacists in addressing the U.S. opioid crisis. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 910-916.	1.5	76
200	Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia. <i>Journal of Community Health</i> , 2020, 45, 239-244.	1.9	37
201	A Call to Action: HCV Treatment of People Who Inject Drugs in the United States. <i>Clinical Infectious Diseases</i> , 2020, 70, 2366-2368.	2.9	4
202	Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 921-929.	0.6	3
203	Initiating Persons into Injection Drug Use in Rural West Virginia, USA. <i>Substance Use and Misuse</i> , 2020, 55, 337-344.	0.7	6
204	Hepatitis C Virus Screening Among Adolescents Attending a Drug Rehabilitation Center. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 437-441.	0.6	9
205	Correlates of Transactional Sex Among a Rural Population of People Who Inject Drugs. <i>AIDS and Behavior</i> , 2020, 24, 775-781.	1.4	29
206	Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2020, 70, 968-972.	2.9	45
207	Motivation to Change and Treatment Participation Among Syringe Service Program Utilizers in Rural Kentucky. <i>Journal of Rural Health</i> , 2020, 36, 224-233.	1.6	8
208	Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. <i>International Journal of Drug Policy</i> , 2020, 85, 102602.	1.6	16
209	Peer influence of injection drug use cessation among dyads in rural eastern Kentucky. <i>International Journal of Drug Policy</i> , 2020, 85, 102604.	1.6	7
210	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	18.1	278
211	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. <i>JAMA Psychiatry</i> , 2020, 77, 493.	6.0	83
212	Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 193-199.	0.5	5
213	Evaluating the impact of Georgia's hepatitis C elimination plan: lessons learned for the global initiative. <i>The Lancet Global Health</i> , 2020, 8, e163-e164.	2.9	6
214	Utilizing Electronic Laboratory Reporting Data to Assess the Burden of Hepatitis C in Arizona. <i>Journal of Public Health Management and Practice</i> , 2020, 26, 562-569.	0.7	2
215	Pregnancy Status, Risk Factors, and Opportunities for Referral to Care Among Reproductive-Aged Women With Newly Reported Chronic Hepatitis C Virus Infection in Tennessee. <i>Public Health Reports</i> , 2020, 135, 90-96.	1.3	6
216	Syringe access and health harms: Characterizing "landscapes of antagonism" in California's Central Valley. <i>International Journal of Drug Policy</i> , 2020, 75, 102594.	1.6	13

#	ARTICLE	IF	CITATIONS
217	Management of Hepatitis C in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 785-790.	0.6	2
218	Evaluating Differences in Opioid and Stimulant Use-associated Infectious Disease Hospitalizations in Florida, 2016–2017. <i>Clinical Infectious Diseases</i> , 2021, 73, e1649-e1657.	2.9	23
219	Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region. <i>Journal of Infectious Diseases</i> , 2020, 222, S354-S364.	1.9	12
220	Human Immunodeficiency Virus Testing, Diagnosis, Linkage to Care, and Prevention Services Among Persons Who Inject Drugs, United States, 2012–2017. <i>Journal of Infectious Diseases</i> , 2020, 222, S268-S277.	1.9	3
221	Healthcare Access and Utilization Among Persons Who Inject Drugs in Medicaid Expansion and Nonexpansion States: 22 United States Cities, 2018. <i>Journal of Infectious Diseases</i> , 2020, 222, S420-S428.	1.9	13
222	Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014. <i>Public Health Reports</i> , 2020, 135, 461-471.	1.3	4
223	Contraceptive use in Appalachian women who use drugs and were recruited from rural jails. <i>Social Work in Health Care</i> , 2020, 59, 365-386.	0.8	8
224	Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. <i>American Journal of Medicine</i> , 2020, 133, e641-e658.	0.6	5
225	Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations. <i>Vaccine</i> , 2020, 38, 8206-8215.	1.7	15
226	The Clinical Microbiology Laboratory and the Opioid Epidemic. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 465-478.	1.9	0
227	Applying the Infectious Diseases Literature to People who Inject Drugs. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 539-558.	1.9	13
228	Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. <i>Liver International</i> , 2020, 40, 2407-2416.	1.9	19
229	Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. <i>Seminars in Liver Disease</i> , 2020, 40, 213-224.	1.8	13
230	State of the Hepatitis C Virus Care Cascade. <i>Clinical Liver Disease</i> , 2020, 16, 8-11.	1.0	16
231	Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. <i>Lancet Microbe</i> , The, 2020, 1, e200-e208.	3.4	74
232	Screening for Hepatitis C Virus: How Universal Is Universal?. <i>Clinical Therapeutics</i> , 2020, 42, 1434-1441.	1.1	7
233	Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women. <i>Obstetrics and Gynecology</i> , 2020, 135, 778-788.	1.2	16
234	Syringe Service Program Utilization, Barriers, and Preferences for Design in Rural Appalachia: Differences between Men and Women Who Inject Drugs. <i>Substance Use and Misuse</i> , 2020, 55, 2268-2277.	0.7	21

#	ARTICLE	IF	CITATIONS
235	Impact of the Opioid Epidemic. <i>Critical Care Clinics</i> , 2020, 36, 753-769.	1.0	12
236	HaRePo (harm reduction by post): an innovative and effective harm reduction programme for people who use drugs using email, telephone, and post service. <i>Harm Reduction Journal</i> , 2020, 17, 59.	1.3	8
237	A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. <i>Harm Reduction Journal</i> , 2020, 17, 64.	1.3	10
238	Novel Recruitment Methods for Research Among Young Adults in Rural Areas Who Use Opioids: Cookouts, Coupons, and Community-Based Staff. <i>Public Health Reports</i> , 2020, 135, 746-755.	1.3	11
239	Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S376-S383.	1.9	11
240	Understanding rural risk environments for drug-related harms: Progress, challenges, and steps forward. <i>International Journal of Drug Policy</i> , 2020, 85, 102926.	1.6	12
241	Widespread septic embolization in injection drug use mitro-aortic infective endocarditis as a remote cause of death. <i>International Journal of Legal Medicine</i> , 2020, 134, 1345-1351.	1.2	3
242	Viral hepatitis in patients on hemodialysis. <i>Seminars in Dialysis</i> , 2020, 33, 254-262.	0.7	4
243	Treatment of Hepatitis C: A New Paradigm toward Viral Eradication. <i>Journal of Pediatrics</i> , 2020, 221, 12-22.e1.	0.9	7
244	A Big Step Forward in Hepatitis C Screening. <i>Clinical Liver Disease</i> , 2020, 15, 149-152.	1.0	3
245	Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs. <i>PLoS ONE</i> , 2020, 15, e0235124.	1.1	5
246	High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department. <i>PLoS ONE</i> , 2020, 15, e0233927.	1.1	18
247	Animal Models Used in Hepatitis C Virus Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3869.	1.8	23
248	Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. <i>International Journal of Drug Policy</i> , 2020, 85, 102701.	1.6	64
249	Individual and network factors associated with HCV treatment uptake among people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 78, 102714.	1.6	19
250	HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. <i>Journal of General Internal Medicine</i> , 2020, 35, 1477-1483.	1.3	12
251	Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis. <i>International Journal of Drug Policy</i> , 2020, 78, 102716.	1.6	32
252	The Health Resources and Services Administration's Ryan White HIV/AIDS Program in rural areas of the United States: Geographic distribution, provider characteristics, and clinical outcomes. <i>PLoS ONE</i> , 2020, 15, e0230121.	1.1	7

#	ARTICLE	IF	CITATIONS
253	Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL. Harm Reduction Journal, 2020, 17, 40.	1.3	21
254	Don't Wait: The Benefits of Early Diagnosis in Perinatal Hepatitis C Virus Transmission. Clinical Infectious Diseases, 2021, 73, e3347-e3348.	2.9	1
255	Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy. Clinical Infectious Diseases, 2021, 73, e3340-e3346.	2.9	18
256	Factors Associated With Testing for Hepatitis C Infections Among a Commercially Insured Population of Persons With HIV, United States 2008–2016. Open Forum Infectious Diseases, 2020, 7, ofaa222.	0.4	1
257	Age- and risk factor-based serologic screening for Hepatitis C virus among an Urban, high-risk population. Journal of Viral Hepatitis, 2020, 27, 1369-1387.	1.0	0
258	Centers for Disease Control and Prevention Recommendations for Hepatitis C Testing: The Need to Adopt Universal Screening in an Appalachian Emergency Department. Academic Emergency Medicine, 2020, 27, 844-852.	0.8	3
259	Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections and Injection Drug Use, Tennessee, USA, 2015–2017. Emerging Infectious Diseases, 2020, 26, .	2.0	26
260	Reported Prevalence of Maternal Hepatitis C Virus Infection in the United States. Obstetrics and Gynecology, 2020, 135, 387-395.	1.2	32
261	We Need a New National Strategy for Hepatitis C Virus Screening. Pediatrics, 2020, 145, .	1.0	3
262	Reasons for assisting with injection initiation: Results from a large survey of people who inject drugs in Los Angeles and San Francisco, California. Drug and Alcohol Dependence, 2020, 209, 107885.	1.6	11
263	Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. Journal of Viral Hepatitis, 2020, 27, 663-670.	1.0	18
264	Animal Models of Hepatitis C Virus Infection. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036970.	2.9	16
265	Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky. Drug and Alcohol Dependence, 2020, 208, 107837.	1.6	11
266	Mitigating the Risk of Infectious Diseases Among Rural Drug Users in Western North Carolina: Results of the Southern Appalachia Test, Link, Care (SALT) Health Care Provider Survey. Journal of Rural Health, 2020, 36, 208-216.	1.6	3
267	Barriers and facilitators to retaining a cohort of street-based cisgender female sex workers recruited in Baltimore, Maryland, USA: results from the SAPPHIRE study. BMC Public Health, 2020, 20, 585.	1.2	10
268	Hepatitis C Testing Among Perinatally Exposed Infants. Pediatrics, 2020, 145, .	1.0	35
269	Infective Endocarditis Among Persons Aged 18–64 Years Living with Human Immunodeficiency Virus, Hepatitis C Infection, or Opioid Use Disorder, United States, 2007–2017. Clinical Infectious Diseases, 2021, 72, 1767-1781.	2.9	25
270	Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. International Journal of Drug Policy, 2021, 88, 102707.	1.6	14

#	ARTICLE	IF	CITATIONS
271	Outcomes of femoral artery ligation for treatment of infected femoral pseudoaneurysms due to drug injection. <i>Journal of Vascular Surgery</i> , 2021, 73, 635-640.	0.6	11
272	Social network predictors of recent and sustained injection drug use cessation: findings from a longitudinal cohort study. <i>Addiction</i> , 2021, 116, 856-864.	1.7	5
273	A multivariate spatio-temporal model of the opioid epidemic in Ohio: a factor model approach. <i>Health Services and Outcomes Research Methodology</i> , 2021, 21, 42-53.	0.8	1
274	High Prevalence of Indications for Pre-exposure Prophylaxis Among People Who Inject Drugs in Boston, Massachusetts. <i>American Journal of Preventive Medicine</i> , 2021, 60, 369-378.	1.6	13
275	Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 185-198.	2.3	9
276	A Population-Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection. <i>Hepatology Communications</i> , 2021, 5, 387-399.	2.0	11
277	Willingness to Participate in At-Home HIV Testing Among Young Adults Who Use Opioids in Rural Appalachia. <i>AIDS and Behavior</i> , 2021, 25, 699-708.	1.4	11
278	Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 71-74.	0.6	2
279	Correlates of Transactional Sex and Violent Victimization among Men Who Inject Drugs in Los Angeles and San Francisco, California. <i>Journal of Urban Health</i> , 2021, 98, 70-82.	1.8	12
280	Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e23080.	1.8	15
281	Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108527.	1.6	10
282	Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108526.	1.6	10
283	Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky. <i>Journal of Rural Health</i> , 2022, 38, 93-99.	1.6	2
284	International Classification of Diseases (ICD) Codes Fail to Accurately Identify Injection Drug Use Associated Endocarditis Cases. <i>Journal of Addiction Medicine</i> , 2022, 16, 27-32.	1.4	3
285	Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. <i>Journal of Urban Health</i> , 2021, 98, 532-537.	1.8	10
286	Harm Reduction for Adolescents and Young Adults During the COVID-19 Pandemic: A Case Study of Community Care in Reach. <i>Public Health Reports</i> , 2021, 136, 301-308.	1.3	8
287	Outbreak of hepatitis B and hepatitis C virus infections associated with a cardiology clinic, West Virginia, 2012-2014. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1458-1463.	1.0	2
288	Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108589.	1.6	16

#	ARTICLE	IF	CITATIONS
289	Syringe Coverage Among People Who Inject Drugs in West Virginia, USA. <i>AIDS and Behavior</i> , 2021, 25, 3377-3385.	1.4	7
290	Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108626.	1.6	14
291	Living at the Confluence of Stigmas: PrEP Awareness and Feasibility Among People Who Inject Drugs in Two Predominantly Rural States. <i>AIDS and Behavior</i> , 2021, 25, 3085-3096.	1.4	13
292	Disparities in Awareness of Hepatitis C Virus Among US Adults: An Analysis of the 2019 Health Information National Trends Survey. <i>Sexually Transmitted Diseases</i> , 2021, 48, 981-985.	0.8	4
293	The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018. <i>American Journal of Public Health</i> , 2021, 111, 949-955.	1.5	25
294	Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. <i>Adolescent Health, Medicine and Therapeutics</i> , 2021, Volume 12, 45-53.	0.7	3
295	Using the electronic medical record to increase testing for HIV and hepatitis C virus in an Appalachian emergency department. <i>BMC Health Services Research</i> , 2021, 21, 524.	0.9	6
296	Rural–Urban Residence and Maternal Hepatitis C Infection, U.S.: 2010–2018. <i>American Journal of Preventive Medicine</i> , 2021, 60, 820-830.	1.6	8
297	Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications. <i>PLoS ONE</i> , 2021, 16, e0252976.	1.1	5
298	Medication assisted therapy and recovery homes. <i>Journal of Prevention and Intervention in the Community</i> , 2021, , 1-13.	0.5	1
299	Responsible Inclusion of Pregnant Individuals in Eradicating HCV. <i>Hepatology</i> , 2021, 74, 1645-1651.	3.6	17
300	Racial disparities in use of non-emergency outpatient care by Medicaid-eligible adults after release from prison: Wisconsin, 2015–2017. <i>Journal of Substance Abuse Treatment</i> , 2021, 126, 108484.	1.5	3
301	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2068-2078.	0.2	16
302	County-level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005–2017. <i>Hepatology</i> , 2021, 74, 582-590.	3.6	7
303	Injections and infections: understanding syringe service program utilization in a rural state. <i>Harm Reduction Journal</i> , 2021, 18, 74.	1.3	9
304	Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. <i>BMJ Open</i> , 2021, 11, e041490.	0.8	2
305	Machine learning takes a village: Assessing neighbourhood-level vulnerability for an overdose and infectious disease outbreak. <i>International Journal of Drug Policy</i> , 2021, 96, 103395.	1.6	13
306	Using Positive Empathy Interventions to Reduce Stigma Toward People Who Inject Drugs. <i>Frontiers in Psychology</i> , 2021, 12, 616729.	1.1	13

#	ARTICLE	IF	CITATIONS
307	Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab374.	0.4	4
308	Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2021, 94, 103198.	1.6	8
309	Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships. <i>Clinical Infectious Diseases</i> , 2022, 74, 993-1003.	2.9	3
310	Methodological approaches for the prediction of opioid use-related epidemics in the United States: a narrative review and cross-disciplinary call to action. <i>Translational Research</i> , 2021, 234, 88-113.	2.2	13
311	Food access among people who inject drugs in West Virginia. <i>Harm Reduction Journal</i> , 2021, 18, 90.	1.3	8
312	Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky. <i>International Journal of Drug Policy</i> , 2021, 95, 103255.	1.6	3
313	Healthcare stigma and HIV risk among rural people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108878.	1.6	20
314	Nursesâ€™ Descriptions of Interactions When Caring for Women With Perinatal Substance Use Disorders and Their Infants. <i>Nursing for Women's Health</i> , 2021, 25, 366-376.	0.3	3
315	Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies. <i>Methods in Molecular Biology</i> , 2019, 1911, 481-503.	0.4	4
316	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.	1.6	6
317	Negative affect, affect-related impulsivity, and receptive syringe sharing among people who inject drugs.. <i>Psychology of Addictive Behaviors</i> , 2020, 34, 734-744.	1.4	4
318	Substance use in rural Central Appalachia: Current status and treatment considerations.. <i>Journal of Rural Mental Health</i> , 2017, 41, 123-135.	0.5	101
319	Examining the Social Context of Injection Drug Use: Social Proximity to Persons Who Inject Drugs Versus Geographic Proximity to Persons Who Inject Drugs. <i>American Journal of Epidemiology</i> , 2017, 186, 970-978.	1.6	17
320	Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, 2986-2990.	2.9	7
321	Quantitative differences between intra-host HCV populations from persons with recently established and persistent infections. <i>Virus Evolution</i> , 2021, 7, veaa103.	2.2	9
322	Spatiotemporal Trends in Opioid Overdose Deaths by Race for Counties in Ohio. <i>Epidemiology</i> , 2021, 32, 295-302.	1.2	15
324	When is an abscess more than an abscess? Syringe services programs and the harm reduction safety-net: a case report. <i>Harm Reduction Journal</i> , 2020, 17, 34.	1.3	6
325	Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. <i>PLoS ONE</i> , 2017, 12, e0177341.	1.1	45

#	ARTICLE	IF	CITATIONS
326	Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas â€” United States, 2013. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 1337-1341.	9.0	184
327	Increases in Acute Hepatitis B Virus Infections â€” Kentucky, Tennessee, and West Virginia, 2006â€”2013. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 47-50.	9.0	107
328	Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission â€” United States and Kentucky, 2011â€”2014. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 705-710.	9.0	113
329	Vital Signs: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs â€” United States. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 1336-1342.	9.0	85
330	State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs â€” United States, 2015â€”2016. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 465-469.	9.0	76
331	Hepatitis C Virus Infection Among Women Giving Birth â€” Tennessee and United States, 2009â€”2014. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 470-473.	9.0	96
332	<i>Notes from the Field</i>: HIV Infection Investigation in a Rural Area â€” West Virginia, 2017. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 257-258.	9.0	59
333	Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Infections Among Persons Who Inject Drugs â€” Six Sites, 2005â€”2016. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 625-628.	9.0	110
334	Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Recommendations and Reports</i> , 2018, 67, 1-31.	26.7	500
335	CDC Recommendations for Hepatitis C Screening Among Adults â€” United States, 2020. <i>MMWR Recommendations and Reports</i> , 2020, 69, 1-17.	26.7	316
336	Understanding the sepsis mortality belt: time to buckle down!. <i>Annals of Translational Medicine</i> , 2016, 4, 319-319.	0.7	4
337	Web-Based Eligibility Quizzes to Verify Opioid Use and County Residence Among Rural Young Adults: Eligibility Screening Results from a Feasibility Study. <i>JMIR Research Protocols</i> , 2019, 8, e12984.	0.5	6
338	Using Web-Based Pin-Drop Maps to Capture Activity Spaces Among Young Adults Who Use Drugs in Rural Areas: Cross-Sectional Survey. <i>JMIR Public Health and Surveillance</i> , 2019, 5, e13593.	1.2	7
339	Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2020, 22, e19703.	2.1	5
340	Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study. <i>JMIR Research Protocols</i> , 2016, 5, e15.	0.5	10
341	Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. <i>Eurosurveillance</i> , 2018, 23, .	3.9	2
342	Demographics of Hepatitis C in Southwest Ohio (2010 to 2015). <i>Hepatitis Monthly</i> , 2016, 16, e37904.	0.1	6
343	Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus. <i>ELife</i> , 2019, 8, .	2.8	10

#	ARTICLE	IF	CITATIONS
344	Outcomes of real-world integrated HCV microelimination for people who inject drugs: an expansion of the punjab model. <i>EClinicalMedicine</i> , 2021, 41, 101148.	3.2	8
345	The Impact of the Drug Epidemic on the Incidence of Sepsis in West Virginia. <i>Cureus</i> , 2018, 10, e3521.	0.2	6
347	Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100088.	0.6	1
348	HCV communication within ego-centric networks of men and women who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109157.	1.6	4
349	Collateral Damage: A Narrative Review on Epidemics of Substance Use Disorders and Their Relationships to Sexually Transmitted Infections in the United States. <i>Sexually Transmitted Diseases</i> , 2021, 48, 466-473.	0.8	11
350	Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyls, drug discernment, and the radical transformation of the illicit opioid market. <i>International Journal of Drug Policy</i> , 2022, 99, 103467.	1.6	30
351	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. <i>Journal of Infectious Diseases</i> , 2020, 222, S741-S744.	1.9	1
352	Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 719-25.	9.0	262
353	Insights in Public Health: Reframing Hepatitis C: Lessons in Successful Public Health Collaboration. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2017, 76, 346-349.	0.4	0
354	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. <i>Gastroenterology and Hepatology</i> , 2018, 14, 687-705.	0.2	2
355	A Simplified Algorithm for the Management of Hepatitis C Infection. <i>Gastroenterology and Hepatology</i> , 2019, 15, 1-12.	0.2	14
356	Identification of People Infected With Hepatitis C Virus Who Have Never Been Diagnosed. <i>Gastroenterology and Hepatology</i> , 2019, 15, 669-671.	0.2	0
357	The Relationship Between Polysubstance Injection Drug Use, HIV Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (PrEP) Among People Who Inject Drugs in Rural West Virginia. <i>Journal of Studies on Alcohol and Drugs</i> , 2020, 81, 740-749.	0.6	5
358	Drugs of Abuse and Their Impact on Viral Pathogenesis. <i>Viruses</i> , 2021, 13, 2387.	1.5	8
359	Plasma virome and the risk of blood-borne infection in persons with substance use disorder. <i>Nature Communications</i> , 2021, 12, 6909.	5.8	8
360	Optical Biosensors for Diagnostics of Infectious Viral Disease: A Recent Update. <i>Diagnostics</i> , 2021, 11, 2083.	1.3	29
361	Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2022, 175, ITC1-ITC16.	2.0	16
362	People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination. <i>PLoS ONE</i> , 2022, 17, e0248850.	1.1	9

#	ARTICLE	IF	CITATIONS
363	Hepatitis C Treatment Knowledge and Practice Among Family Medicine Physicians in Wisconsin During the Current Hepatitis C Epidemic. <i>Wisconsin Medical Journal</i> , 2021, 120, 106-113.	0.3	0
364	Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4158.	1.2	1
365	Testing a digitally distributed method to recruit a network of community organizations to fight the consequences of the drug epidemic: A study in 13 American states. <i>Journal of Community Psychology</i> , 2022, 50, 3455-3469.	1.0	0
366	Opioid Use Disorder Diagnosis and Management. , 2022, 1, .		5
367	Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. <i>PLoS ONE</i> , 2022, 17, e0265811.	1.1	0
368	Viral hepatitis: Past, present, and future. <i>World Journal of Gastroenterology</i> , 2022, 28, 1405-1429.	1.4	29
369	Genotype Distribution and Demographic Characteristics of Hepatitis C Virus NAT Yield Cases among US Blood Donors. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	1
371	Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection. <i>Obstetrics and Gynecology</i> , 2022, 139, 916-918.	1.2	12
372	Egocentric network characteristics of people who inject drugs in the Chicago metro area and associations with hepatitis C virus and injection risk behavior. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	7